American Society of Hematology

Schedule and Program for the ASH Meeting on Lymphoma Biology

The following 2018 ASH Meeting on Lymphoma Biology program is preliminary and subject to change.

2:00 p.m. - 7:00 p.m.
Registration
5:20 p.m. – 6:05 p.m.
Opening Keynote Address

Michael Reth, PhD, University of Freiburg
B Cell Antigen Receptor Signaling of Normal and Transformed B Cells
6:05 p.m. – 8:00 p.m.
Welcome Reception and Exhibits
7:00 a.m. – 5:00 p.m.
Registration
7:00 a.m. – 8:00 a.m.
Breakfast and Exhibits
10:00 a.m. – 10:15 a.m.
Networking Coffee Break
10:15 a.m. – 12:15 p.m.
Microenvironment Influences in Lymphoma

Chair:
Freda K. Stevenson, DPhil, University of Southampton Medical School

Speakers:
Hans-Guido Wendel, MD, Memorial Sloan Kettering Cancer Center
Immune Receptor Mutations in Lymphoma

Karin Tarte, PhD, INSERM U1236 & CHU Rennes
Follicular Lymphoma Microenvironment: Role in Pathogenesis and Clinical Impact

Ron Levy, MD, Stanford School of Medicine
Combining Intratumoral Injections of Toll-Like Receptor Agonists With Checkpoint Antibodies
12:15 p.m. – 1:15 p.m.
Lunch and Exhibits
1:15 p.m. – 1:45 p.m.
Company Presentations
1:45 p.m. – 4:00 p.m.
Continuing Conversations
4:00 p.m. – 5:30 p.m.
Poster Presentations
5:30 p.m. – 7:00 p.m.
Dinner (provided)
7:00 p.m. – 9:00 p.m.
Discovery of Novel Pathogenic Mechanisms and Therapies in Lymphoma

Chair:
Ari Melnick, MD, Weill Cornell Medical College

Speakers:
Ari Melnick, MD, Weill Cornell Medical College
Epigenetics in Lymphoma

Laura Pasqualucci, MD, Columbia University
Genetic Basis of Epigenetic Dysregulation in Germinal Center-Derived Lymphomas

Suzanne Cory, PhD, Walter and Eliza Hall Institute of Medical Research
From Translocation to Therapy: How Understanding the BCL-2 Cell Life/Death Switch Is Leading to More Effective Therapy
7:00 a.m. – 5:00 p.m.
Registration
7:00 a.m. – 8:00 a.m.
Breakfast and Exhibits
9:45 a.m. – 10:00 a.m.
Networking Coffee Break
10:00 a.m. – 12:00 noon
Molecular Targeting

Chair:
Louis Staudt, MD, PhD, National Cancer Institute, National Institutes of Health

Speakers:
Anthony Letai, MD, PhD, Dana-Farber Cancer Institute
Mitochondria Tell You What You Need to Know to Treat Lymphoid Cancers

Andreas Strasser, MSc, PhD, FAA, Walter and Eliza Hall Institute of Medical Research
Toward Targeting the Pro-Survival BCL-2 Family Members for Cancer Therapy

Roberto Chiarle, MD, Boston Children's Hospital
Targeted Therapy and Resistance in Lymphoma
12:00 noon – 1:00 p.m.
Lunch and Exhibits
1:00 p.m. – 1:30 p.m.
Company Presentations
3:15 p.m. – 3:45 p.m.
Networking Coffee Break
3:45 p.m. – 5:15 p.m.
Poster Presentations
5:15 p.m. – 6:45 p.m.
Dinner (provided)
6:45 p.m. - 8:45 p.m.
T-Cell Lymphoma

Chair:
Kojo S.J. Elenitoba-Johnson, MD, University of Pennsylvania

Speakers:
Laurence L. de Leval, MD, PhD, Lausanne University Hospital
Pathology and Genetic Lesions

Teresa Palomero, PhD, Columbia University
The Role of the RHOA G17V Mutation in the Pathogenesis of AITL

Megan Lim, MD, PhD, University of Pennsylvania Perelman School of Medicine
Novel Insights Into Anaplastic Lymphoma Kinase-Mediated Pathogenetic Mechanisms in Anaplastic Large Cell Lymphoma
7:00 a.m. – 1:00 p.m.
Registration
7:00 a.m. – 8:00 a.m.
Breakfast and Exhibits
8:00 a.m. – 10:00 a.m.
B-Cell Malignancies

Chair:
Laura Pasqualucci, MD, Columbia University

Speakers:
Bertrand Nadel, PhD, Centre D'Immunologie De Marseille-Luminy
Integrative Single-Cell Analysis: A New Prism to Decipher Follicular Lymphoma Heterogeneity

Ralf Kuppers, PhD, University of Duisburg - Essen
Hodgkin Lymphoma

Elias Campo, MD, PhD, University of Barcelona
Molecular Heterogeneity in Mantle Cell Lymphoma
10:00 a.m. – 10:20 a.m.
Networking Coffee Break
10:20 a.m. – 10:50 a.m.
Company Presentations
10:50 a.m. – 12:50 p.m.
Chronic Lymphocytic Leukemia

Chair:
Elias Campo, MD, PhD, University of Barcelona

Speakers:
Silvia Deaglio, MD, PhD, University of Turin
Microenvironmental Interactions in Chronic Lymphocytic Leukemia

Davide Rossi, MD, PhD, Oncology Institute of Southern Switzerland
Clinical Implications of Gene Mutations in Chronic Lymphocytic Leukemia

Francesco Forconi, MD, PhD, University of Southampton
B-Cell Receptor-Associated Kinase Inhibitors in Chronic Lymphocytic Leukemia
12:50 p.m. – 1:10 p.m.
Closing Remarks From Program Co-Chairs
back to top